Carleen Cullinane
Overview
Explore the profile of Carleen Cullinane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
3563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuen D, Feeney O, Noi L, Shengule S, McLeod V, Reitano P, et al.
ACS Nano
. 2025 Feb;
19(6):6044-6057.
PMID: 39910852
Dendrimers are branched macromolecular structures that are useful nanocarriers for small-molecule drugs, such as cancer therapeutics. Their small size permits penetration into solid tumors, coupled with functionalization with a low-fouling...
2.
Rudd S, Van Zuylekom J, Cullinane C, Blyth B, Donnelly P
Chem Sci
. 2025 Feb;
16(9):3998-4005.
PMID: 39898305
Over-expression of Human Epidermal Growth Factor Receptor 2 (HER2) is associated with a significant proportion of breast cancers. Targeting HER2 is possible with a monoclonal antibody called trastuzumab but metastatic...
3.
Noor A, McGowan E, Van Zuylekom J, Cullinane C, Roselt P, Hicks R, et al.
EJNMMI Radiopharm Chem
. 2024 Nov;
9(1):80.
PMID: 39589414
Background: Carbonic Anhydrase IX (CAIX) is a zinc metalloenzyme that is over-expressed in many cancers making it a valid target for targeted diagnostic imaging with Positron Emission Tomography (PET). The...
4.
Maclachlan K, Gitareja K, Kang J, Cuddihy A, Cao Y, Hein N, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200771.
PMID: 38596309
The high rates of protein synthesis and processing render multiple myeloma (MM) cells vulnerable to perturbations in protein homeostasis. The induction of proteotoxic stress by targeting protein degradation with proteasome...
5.
Waldeck K, Van Zuylekom J, Cullinane C, Gulati T, Simpson K, Tothill R, et al.
Theranostics
. 2023 Sep;
13(14):4745-4761.
PMID: 37771787
Peptide receptor radionuclide therapy (PRRT) using Lutetium-DOTA-octreotate (LuTate) for neuroendocrine tumours (NET) is now an approved treatment available in many countries, though primary or secondary resistance continue to limit its...
6.
Corlett A, Pinson J, Rahimi M, Van Zuylekom J, Cullinane C, Blyth B, et al.
J Med Chem
. 2023 Jul;
66(15):10289-10303.
PMID: 37493526
Peptide receptor radionuclide therapy (PRRT) is a promising form of systemic radiation therapy designed to eradicate cancer. Cholecystokinin-2 receptor (CCKR) is an important molecular target that is highly expressed in...
7.
Smith L, Parmenter T, Kleinschmidt M, Kusnadi E, Kang J, Martin C, et al.
Nat Commun
. 2022 Mar;
13(1):1100.
PMID: 35232962
Despite the success of therapies targeting oncogenes in cancer, clinical outcomes are limited by residual disease that ultimately results in relapse. This residual disease is often characterized by non-genetic adaptive...
8.
Wong S, Raleigh J, Callahan J, Vergara I, Ftouni S, Hatzimihalis A, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-14.
PMID: 35172485
Purpose: Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by...
9.
Lau P, Cullinane C, Jackson S, Walker R, Smith L, Slater A, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944961
Despite the success of immune checkpoint inhibitors that target cytotoxic lymphocyte antigen-4 (CTLA-4) and programmed-cell-death-1 (PD-1) in the treatment of metastatic melanoma, there is still great need to develop robust...
10.
Liu Z, Martin J, Liauw W, McLachlan S, Link E, Matera A, et al.
Eur J Clin Pharmacol
. 2021 Sep;
78(1):53-64.
PMID: 34480602
Background: Body surface area (BSA)-based dosing of irinotecan (IR) does not account for its pharmacokinetic (PK) and pharmacodynamic (PD) variabilities. Functional hepatic nuclear imaging (HNI) and excretory/metabolic/PD pharmacogenomics have shown...